Gregory J. Downing
National Institutes of Health
13 Papers
343 Citations
Gregory J. Downing is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Wortmannin & Phosphatidylinositol. The author has an hindex of 11, co-authored 13 publications.
Chat about Author
Papers
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework*
Arthur J. Atkinson,Wayne A. Colburn,Victor G. DeGruttola,David L. DeMets,Gregory J. Downing,Daniel F. Hoth,John A. Oates,Carl C. Peck,Robert T. Schooley,Bert A. Spilker,Janet Woodcock,Scott L. Zeger +11 more
TL;DR: Biomarker measurements provide an avenue for researchers to gain a mechanistic understanding of the differences in clinical response that may be influenced by uncontrolled variables (for example, drug metabolism).
6.5K
Characterization of a soluble adrenal phosphatidylinositol 4-kinase reveals wortmannin sensitivity of type III phosphatidylinositol kinases.
TL;DR: Findings indicated that type III rather than type II PtdIns 4-kinases are responsible for the maintenance of the precursor phospholipids required for intracellular signaling through the inositol phosphate/Ca2+ pathway.
122
Isolation and Molecular Cloning of Wortmannin-sensitive Bovine Type III Phosphatidylinositol 4-Kinases
TL;DR: The molecular cloning of these novel WT-sensitive type III PI 4-kinases will allow detailed analysis of their signaling and other regulatory functions in mammalian cells.
85
Technical assessment of the first 20 years of research using mouse embryonic stem cell lines.
TL;DR: The widespread influence of mouse ES cells as an enabling technology is examined by highlighting their effect on drug development paradigms, directed differentiation to treat specific diseases, nuclear transfer protocols used in cloning, and establishment of methodologies for isolating non‐rodent ES cells.
71
Medical nanotechnology: shortening clinical trials and regulatory pathways?
Mauro Ferrari,Gregory J. Downing +1 more
TL;DR: One promising nanoscale technology under development may provide real-time, in vivo measurements of apoptosis, and thus may afford an early signal of therapeutic efficacy, both in human clinical trials and in preclinical screening.
37